



Overseas Regulatory Announcement – Disposal Transaction

HUTCHMED (China) Limited (“[HUTCHMED](#)”) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 28, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. As described in the HUTCHMED announcement entitled “Major Transaction in relation to the Disposal of 45% Equity Interest in Shanghai Hutchison Pharmaceuticals Limited”, the text relates to the timing of dispatch of EGM circular.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Alex Shaw

+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500

HSBC

Joint Broker

Simon Alexander / Alina Vaskina / Arnav Kapoor

+44 20 7991 8888

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

**MAJOR TRANSACTION
IN RELATION TO
THE DISPOSAL OF 45% EQUITY INTEREST IN
SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED**

TIMING OF DISPATCH OF CIRCULAR

Reference is made to the announcement of HUTCHMED (China) Limited (the “**Company**”) dated January 1, 2025 (the “**Announcement**”) in relation to the proposed disposal of 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

In the Announcement, it was mentioned that the Circular containing, among other things, (i) further details on the terms of the Proposed Disposal; and (ii) other information as required under the Listing Rules together with a notice convening the EGM, was expected to be dispatched to the Shareholders on or before January 28, 2025.

GP Health Service Capital has notified the Seller that additional time is required for it to designate the GP Purchaser Fund and the Designated Purchaser, taking into account the Chinese New Year holidays. In view of this, the Company currently expects that the Circular will be dispatched to the Shareholders on or before February 28, 2025.

The Proposed Disposal is subject to all of the conditions under the Agreements being satisfied (or, if applicable, waived) and therefore may or may not become unconditional. If any of the conditions under the Agreements is not satisfied (or, if applicable, waived), the Proposed Disposal will not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, January 28, 2025

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU

*(Chief Executive Officer and
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny
(Chief Financial Officer)

Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Mr Paul Rutherford CARTER

(Senior Independent Director)

Dr Renu BHATIA

Dr Chaohong HU

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony